RedHill Biopharma (RDHL) Total Debt (2020 - 2022)

RedHill Biopharma (RDHL) has 3 years of Total Debt data on file, last reported at $230.4 million in Q4 2022.

• On a quarterly basis, Total Debt rose 175.57% year-over-year to $230.4 million in Q4 2022; TTM through Dec 2022 was $230.4 million, a 175.57% increase from a year earlier, with the FY2022 full-year figure at $230.4 million, up 175.57% from the prior year.
• Total Debt for Q4 2022 stood at $230.4 million, up from $113.9 million in the prior quarter.
• Over the last five years, Total Debt for RDHL reached as high as $230.4 million in Q4 2022 and fell as low as $78.2 million in Q1 2020.
• Historically, Total Debt has averaged $97.3 million across 3 years, with a median of $83.3 million in 2021.
• Across the five-year window, Total Debt advanced 2.74% in 2021 and soared 175.57% in 2022, its largest moves.
• Year by year, Total Debt stood at $81.4 million in 2020, then increased by 2.74% to $83.6 million in 2021, then surged by 175.57% to $230.4 million in 2022.
• Per Business Quant data, the three most recent Total Debt figures were $230.4 million in Q4 2022, $113.9 million in Q3 2022, and $85.5 million in Q2 2022.